Healthcare · Profile from Healthcare Research Companion
Oak Street Health
The Chicago company that built a national chain of primary-care centres for low-income and dual-eligible Medicare seniors, paid almost entirely by full-risk capitation from Medicare Advantage plans. It was the clearest public-market test of the "de novo senior primary care" model: a 2020 IPO, a ~$10.6bn sale to CVS Health in 2023 at the top of the value-based-care cycle, a $60m kickback settlement over its agent-referral marketing, and a ~$5.7bn goodwill impairment (shared with Signify Health) and centre closures inside CVS by 2025.
At a glance
- Founded
- 2012, Chicago, Illinois; first centre opened in 2013 in Chicago's Edgewater neighbourhood (reported)
- Founders
- Mike Pykosz (CEO; formerly a principal at The Boston Consulting Group, Harvard Law), Dr Griffin Myers (Chief Medical Officer; emergency-medicine physician, Chicago Booth MBA) and Geoff Price (COO; formerly at Bain & Company and Nautic Partners) (backgrounds from third-party profiles; verify)
- Headquarters
- Chicago, Illinois
- Ownership / structure
- Venture- and growth-equity-backed private company (2012–2020); public company, NYSE: OSH (IPO August 2020); wholly owned subsidiary of CVS Health since May 2, 2023, inside CVS's Health Care Delivery unit
- Leadership (2026)
- Mike Pykosz left CVS at the end of 2024 (announced November 2024); Dr Sreekanth Chaguturu, CVS's chief medical officer, became President of Health Care Delivery, overseeing Oak Street (reported; verify current Oak Street leadership)
- Segment and buyer
- Provider: value-based senior primary care. Paid by Medicare Advantage plans under capitation (percentage-of-premium) contracts, and by traditional Medicare through CMS's Direct Contracting/ACO REACH model
- Payer and patient
- Medicare Advantage insurers (Humana historically the largest, ~45% of capitated revenue in 2020, derived from filings), traditional Medicare (ACO REACH), small fee-for-service book; patients are older adults, many low-income or dually eligible for Medicaid
- Scale
- 169 centres in 21 states and ~159,000 at-risk patients (~224,000 total) at end-2022; ~246 centres before the 16 closures announced in October 2025 and ~230 in 27 states after them (company statement via Supermarket News)
- Capital / market cap
- Private growth capital from investors including Newlight Partners, General Atlantic and Humana (verify round sizes); IPO at $21/share raised ~$328m (August 2020); $920m 0% convertible notes (March 2021); market value peaked around ~$15bn in 2021 (verify); CVS paid $39/share, ~$10.6bn including debt
- Revenue
- 2020: $882.8m; 2021: $1,432.6m; 2022: $2.16bn (net loss ~$510m); no separate disclosure inside CVS
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2012
Founding Full Risk Senior Primary Care
Founding / launch of business model
2015
General Atlantic Growth Equity
Funding round (growth equity) and multi-state expansion
2020
NYSE IPO
IPO
2021
Build Out and Convertible Notes
Expansion / financing
2021
Direct Contracting ACO REACH
Partnership (CMS Innovation Center payment model)
2023
CVS Acquisition
Acquisition (Oak Street as target)
2024
False Claims Act Settlement
Regulatory settlement
2025
Impairment and Closures
Restructuring (impairment, centre closures, layoffs, slower growth)